DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación
Artículo científico (JournalArticle)
A carnitine-based BODIPY photosensitizer
Organelle-selective photodynamic therapy (PDT) has emerged as a promising approach to enhance the precision and efficacy of cancer treatment by targeting key cellular structures. In this study, we report the design of a novel carnitine-based BODIPY photosensitizer, probe 1, which retains mitochondrial selectivity while acting as both a fluorescent probe and a potent photosensitizer. Building on our previously developed mitochondria-targeting probe (R)-BCT-2, which is transported into the mitochondrial matrix by the inner membrane protein carnitine-acylcarnitine translocase (CAC), probe 1 incorporates two bromine atoms that enhance intersystem crossing, leading to a singlet oxygen quantum yield of ∼80%, while retaining sufficient fluorescence for effective cell staining in fluorescence microscopy. Theoretical calculations indicate that the carnitine moiety distorts chromophore planarity, reducing oscillator strength but enhancing spin-orbit coupling, which, together with the extended triplet lifetime, contributes to increased phototoxicity. Probe 1 co-localizes in both mitochondria and, to a lesser extent, in lysosomes, and this dual targeting may synergistically enhance phototoxic activity by amplifying cellular stress responses. Importantly, probe 1 demonstrated high phototoxicity upon green light irradiation, with IC50 values of 52 nm under normoxia and 117 nm under hypoxia, while remaining non-cytotoxic in the dark. These results suggest that probe 1 is a promising candidate for organelle-targeted PDT, particularly in hypoxic tumor environments where its dual organelle targeting could enhance therapeutic efficacy., We gratefully acknowledge financial support from MCIN/AEI/ 10.13039/501100011033 (projects PID2020-114347RB-C31, PID2020114347RB-C32, PID2022-136231NB-I00, PID2023-151388OB-I00; and TED2021-132122B-C22, which is co-funded by the European Union ‘‘NextGenerationEU/PRTR’’), Gobierno Vasco-Eusko Jaurlaritza (project IT1639-22), and Instituto de Salud Carlos III/co-funded by the European Union ERDF/ESF, ‘‘A way to make Europe‘‘/’’Investing in your future’’ (project 20/01754). L. M., A. D.-A and T. C. thank MCIN (PRE2018-086180 and PRE2020-092036), and Consejerıa de Ciencia, Innovación y Universidad (Principado de Asturias) (BP20033), for predoctoral contracts, respectively., Peer reviewed
Proyecto:
AEI / Plan Estatal de Investigación Científica y Técnica y de Innovación 2017-2020 PID2020-114347RB-C31
,
AEI / Plan Estatal de Investigación Científica y Técnica y de Innovación 2017-2020 PID2020-114347RB-C32
,
AEI / Plan Estatal de Investigación Científica y Técnica y de Innovación 2021-2023 PID2022-136231NB-I00
,
AEI / Plan Estatal de Investigación Científica y Técnica y de Innovación 2021-2023 TED2021-132122B-C22